TABLE 1.
High 4-year risk | Low 4-year risk | Two-tailed p-value | |
Sample size | 74 | 93 | |
Age (years) | 52.7±15.5 | 47.0±14.3 | 0.015 |
Female (%) | 71.6 | 75.3 | |
Race | |||
White | 42 | 53 | 0.992 |
Asian | 10 | 24 | |
Hispanic | 11 | 11 | |
Black | 5 | 3 | |
Other | 6 | 2 | |
PAH subtype | |||
Connective tissue disease | 25 | 27 | 0.997 |
Idiopathic PAH | 19 | 27 | |
Drug and toxins | 13 | 15 | |
Congenital heart disease | 8 | 17 | |
Portopulmonary hypertension | 8 | 4 | |
Hereditary PAH | 1 | 3 | |
NYHA functional class | |||
Class I | 4 | 5 | 0.942 |
Class II | 11 | 42 | |
Class III | 46 | 37 | |
Class IV | 13 | 9 | |
Haemodynamics | |||
mPAP (mmHg) | 50.8±16.2 | 50.9±16.6 | 0.969 |
PVR (dyn·s·cm−5) | 11.2±7.14 | 11.3±6.59 | 0.925 |
Cardiac index (L·min−1·m−2) | 2.27±0.82 | 2.24±0.67 | 0.795 |
Mean right atrial pressure (mmHg) | 9.70±6.33 | 7.89±4.78 | 0.037 |
PCWP (mmHg) | 12.2±5.72 | 10.5±4.09 | 0.027 |
Timing from | |||
Diagnosis (years) | 3.1±3.9 | 4.5±5.4 | 0.053 |
Symptom onset (years) | 4.4±4.8 | 6.0±5.4 | 0.051 |
Therapy | |||
Treatment-naïve | 23 | 28 | 0.999 |
Monotherapy | 21 | 28 | |
Dual therapy | 22 | 26 | |
Triple therapy | 8 | 11 |
Data are presented as n or mean±sd, unless otherwise stated. PAH: pulmonary arterial hypertension; NYHA: New York Heart Association; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; PCWP: pulmonary capillary wedge pressure.